


INDEX



A

- Abatecept, 7
- Abbreviated New Drug Application, 12, 73–74
- AbbVie, 122, 132, 133, 167
- Abciximab, blockbuster, 2
- ABP 215, 102, 104, 107
- ABP 798, 86
- Academy of Managed Care Pharmacy, 122
- Adalimumab, 147
 - administration of, 133
 - adverse reactions to, 115
 - biosimilar for, 6, 49, 86
 - as blockbuster, 2, 3, 4
 - clinically important antibodies to, 118
 - expression system for, 23
 - IPR and, 132, 133
 - manufacturing changes and, 27
 - mechanism of action in, 50
 - modifications of, 134
 - new biosimilars for, 168
 - price increases for, 7
- Adalimumab-adbm, 86, 121, 167
- Adalimumab-atto, 50–51, 86, 121, 133, 161, 167
 - clinical studies supporting approval of, 104
 - indication coverage for, 100–101, 102
 - missing data in, 97
 - single switch study of, 109
- Adverse events, 123
 - biologic, 113–115
- Afibercept, 7
- Aggregation, 43
- Alirocumab, blockbuster, 2
- Allergen, 133
- America Invents Act, 132
- American experience
 - approval processes and, 74–75
 - biosimilar approvals and, 72–74
 - biosimilar guidances and, 76
 - generic small molecules, comparable biologics and, 72–75
 - interchangeability and, 76–77, 82–83
 - mechanisms of action and, 72
 - overview of, 71
- Amgen, 122, 133, 167
- Analytical characterization, statistical approach to, 35–36
- Analytical ultracentrifugation, 43
- Aripiprazole, exclusivity, 5
- Assays
 - binding, 49
 - in vitro biological activity/mechanism of action, 49
- Atezolizumab, blockbuster, 2
- Atorvastatin
 - as blockbuster, 3, 4
 - exclusivity and, 5
- Average sales price, 144, 145–146
- Average wholesale price, 144

B

B1695500, 86

B1695502, 86

Balanced Budget Act of 2018, 148

Bevacizumab

adverse reactions to, 115

biosimilar for, 6, 86

as blockbuster, 3

expression system for, 23

manufacturing changes and, 27

new biosimilars and, 168

price increase for, 7

Bevacizumab-awwb, 86, 121

clinical trials for, 107

indication coverage for, 100–101, 102

licensure of, 104

Biobetter, 134

Biologic qualifier, 121–122

Biologics

approvals of, 74

clinical importance antibodies to, 118

comparability and, 25–28, 29

cost of, 4–5

growth of, 1–2

recombinant derived, 21

transition and, 73

Biologics and Biosimilars Collective Intelligence Consortium, 122

Biologics License Applications, 158

Biologics Price Competition and Innovation Act, 5, 12, 161

approvals and, 72

aspects of, 73

biosimilar pathway and, 85

biosimilar variances and, 122–123

exclusivity and, 72, 129

guidance documents and, 76

interchangeability and, 80–81

interchangeability in practice and, 82

overview of, 71–72

Biosimilarity

analytical characterization and, 33–34

analytics and, 33

clinical data and, 105

definition of, 71

goal posts in, 34

meeting standard of, 49–51

statistical analytical characterization and, 35–36

Biosimilars, 5–6, 11–18

analytical characterization and, 51

approvals of, 15–16

approved in other countries, 58

assessing Fab vs. Fc regions in, 49–51

compared to generics, 15

compared to originator reference

biologic, 35

definition of, 71

development milestones for, 163

Europe's experience with, 15

exclusivity and, 129

familiarity with, 16

high cost of, 13–14

ligand conjunction and, 44–45

management infrastructure and, 17

Medicare reimbursement for, 146–147

naming, labeling of, 63, 64

next wave of, 168

operational differences compared to generics, 16

perceived drawbacks of, 11–12

pharmacists support for, 17

reimbursement (theoretical) for, 145–146

savings with, 16–17

in 2023, 167–168

value checklist for, 149

variability of, 25–26
 Biosimilars Forum, 161
 Blockbuster drugs, 3–4
 growth of, 4–9
 Boehringer-Ingelheim, 122, 167
 Brand names, 120
 Branded drugs Medicare reimbursement,
 146
 Bridging trials, 100–102
 British Society of Gastroenterology, 61
 British Society of Rheumatology, 62
 Brown bagging, 145
 Buy and bill model, 145

C

Capillary electrophoresis-sodium dodecyl
 sulfate, 43
 Cell expression systems, 22
 Certolizumab pegol
 manufacturing changes and, 27
 price increases for, 7
 Cetuximab
 amino acid sequence errors and, 41
 expression system for, 23
 manufacturing changes and, 27
 price increases for, 7
 Charge heterogeneity, 40
 Chinese hamster ovary cells, 22–24
 CHS-0214, 86
 CHS-1701, 86
 Circular dichroism, 41
 Clinical data, 105–107, 158
 Clinical practice, 102–105, 134
 Clinical trials, 91, 127
 bridging trials and, 100–102
 clinical pharmacology data in, 92
 construction of, 109
 equivalence study design in, 95
 extrapolation in, 97–98

FDA's approach to, 91–93
 global, 99–100
 immunogenicity data in, 93, 94
 labeling and, 98–99
 missing data management in, 97
 pharmacodynamics and, 93–94
 pharmacokinetics and, 93–94
 pharmacology studies in action,
 93–95
 scientific considerations in, 92
 superiority vs. equivalence studies in,
 96–97
 Clopidogrel
 as blockbuster, 3, 4
 exclusivity and, 5
 Comparability, 25–28, 29
 Core name, 120
 Coverage Gap Discount Program, 147
 Creutzfeldt-Jakob disease, 116
 Critical quality attributes, 34
 CT-P10, 86
 Cyclosporine ophthalmic solution, 133

D

Daclizumab, blockbuster, 2
 Darbepoetin
 expression system for, 23
 extended dosing and, 134
 price increases for, 7
 Data collection, 122–123
 Denosumab, 7
 Differential scanning calorimetry, 42
 Distribution channel selection, 141
 Disulfide bonds, 44, 45
 Donut hole, 147
 Drift, 24
 Drug acquisition financial considerations,
 143
 Drug Price Competition and Patent Term
 Restoration Act, 11, 127

E

Eculizumab, 7
 EP06-101, 94
 EP06-103, 94
 EP06-105, 94
 EP06-109, 94
 EP06-302, 94
 Epoetin
 European Union and, 59
 pure red cell aplasia and, 116
 Epoetin alfa
 adverse reactions to, 115, 116–117
 biosimilar for, 6, 86
 as blockbuster, 2, 3
 immunogenicity and, 118
 price increases for, 7
 Epoetin alfa-cgkn, 121
 Erythropoietin, 118
 Escherichia coli (E coli)
 expression cells, 22–23
 manufacturing success with, 23
 Esomeprazole
 as blockbuster, 3
 exclusivity and, 5
 Etanercept, 147
 adverse reactions to, 115
 biosimilar for, 6, 49, 86
 as blockbuster, 3, 4
 clinically important antibodies to, 118
 expression system for, 23
 mechanism of action for, 98
 modifications of, 134
 price increases and, 7
 Etanercept-szszs, 82, 86, 105, 121, 161
 clinical trials for, 105
 indication coverage for, 100–101, 102
 European Crohn's and Colitis Organiza-
 tion, 61, 63, 162

European League Against Rheumatism, 62
 European Medicines Agency, 15, 51, 57
 infliximab-dyyb and, 98
 Working Party on Similar Biologic
 Medicinal Products, 60
 European Public Assessment Report, 27
 Exclusivity, 78, 127–128
 duration of, 5, 72, 73
 interchangeability and, 80
 new drug applications and, 128
 other and, 128
 Expression systems, 22–23
 Extrapolation, 63, 64
 clinical trials and, 97–98
 mechanisms of action and, 98
 understanding, 98–99

F

Field flow fractionation, 43
 Filgrastim
 biosimilars for, 6, 49, 57–58, 60, 86
 clinical trials for, 104
 expression system for, 23
 global biosimilars for, 57
 mechanism of action for, 98
 United Kingdom's experience with, 59
 Filgrastim-bflm, 121
 Filgrastim-dyyb, 82–83
 Filgrastim-jcwp, 121
 Filgrastim-sdnz, 58, 86, 121, 161
 indication coverage for, 100–101, 102
 PK, PD studies and, 93–94
 switching studies for, 107–109
 Filgrastim-vkzt, 121
 FK238, 86
 Food and Drug Administration (FDA), 1
 analytical characterization and simi-
 larity assessments by, 52

ANDA and, 12–13
 biologic adverse events and, 113–114
 biosimilar analytical characterization
 factors and, 35
 biosimilar safety and immunogenicity
 and, 118–119
 biosimilars approved or pending with,
 86
 biosimilars and originator biologics
 and, 120–122
 BPCI implementations and, 77, 78, 79
 clinical pharmacology data and, 78
 clinical trials and, 91–93
 comparability and, 25–28
 core name and, 120
 demonstrating biosimilarity and, 51
 evaluating analytical similarity and, 80
 exclusivity and, 78, 127
 extrapolation and, 97–98
 formal meetings with, 77
 guidance documents of, 76–80
 interchangeability and, 79, 81
 labeling and, 79
 naming biological products and, 78
 Orange Book of, 13
 Purple Book of, 83–84
 quality considerations in biosimilarity
 and, 77
 scientific considerations in biosimi-
 larity and, 77
 Sentinel Initiative of, 122
 statistical analytical characterization
 and, 35–36
 Formulary management, 14, 153
 approval processes for, 158
 biosimilar naming, dosage forms and,
 153–154
 clinical data and, 158
 conversion cost and, 159–160

 critical document elements and,
 154–157
 dosage forms differences and, 159
 interchangeability and, 160
 inventory and, 159
 pharmacovigilance and, 160
 product naming and, 158
 similar biosimilar elements and, 157
 Fourier transform infrared spectroscopy,
 41, 42
 Fructose, 48
 Fusion proteins, global biosimilars, 57

G

Generics

 acceptance of, 17
 annual savings for, 14
 experience with, 12–13
 initial issues, concerns with, 13
 Medicare reimbursement for, 146
 model for, 60
 prescriptions filled with, 12

Global experience

 for biosimilar introductions globally,
 57–59
 biosimilar position statements on,
 61–63
 biosimilar success in, 59–60
 clinician, physician education, under-
 standing in, 60
 developing markets, safety issues in,
 66
 extrapolation, naming, interchangea-
 bility in, 63
 financial performance in, 59
 interchangeability in, 82–83

Glucagon, expression system for, 23

Glycosylation

impact on pharmacokinetics, pharmacodynamics, 48

PTMs, 44–48

Golimumab

manufacturing changes and, 27

price increases for, 7

GP2013, 86

Group purchasing organizations, 142

Growth hormone, clinically important antibodies to, 118

H

Hatch-Waxman Amendments, 127

Health Canada, 51

and infliximab–dyyb, 98

Healthcare Common Procedure Coding System, 145–146

High pressure liquid chromatography, 40

Higher molecular weight/aggregation, 39

Higher order structure, 38, 41–42

Histidine, 44

Hospitals (inpatient), 143, 144

Hospitals (outpatient), 143, 144

Human insulin, 1

Hydrogen deuterium exchange, 41, 42

I

Immune-mediated reactions, 117–118

Immunogenicity, 113, 115–116, 118

biosimilars and, 118

clinical trials and, 93

focus on, 115–116

Infliximab

adverse reactions to, 115

biosimilar for, 6, 49, 60, 63, 86

as blockbuster, 2, 3, 4

clinically important antibodies to, 118

expression system for, 23

manufacturing changes and, 27

mechanism of action in, 50

minimally clinically important difference, 95

modifications of, 134

new biosimilars for, 168

NOR–SWITCH trial of, 83

price increases for, 7

Infliximab-abda, 86, 121

clinical studies supporting, 106

indication coverage for, 100–101, 102

patent dance and, 131

single switch study and, 109

Infliximab-dyyb, 49–51, 57–58, 86, 121, 161

clinical studies supporting approval of, 103

extrapolation and, 98

global studies of, 99–100

indication coverage for, 100–101, 102

single switch study for, 109

Information exchange, 130

Insulin, 21

regular, expression system for, 23

Insulin aspart, 75

Insulin detemir, 75

Insulin glargine

as blockbuster, 3

drug approval of, 75

expression system for, 23

price increases for, 7

Insulin lispro, 75

Intention to treat, 97

Inter Partes review, 132–133

Interchangeability, 63, 66, 76–77, 79, 86

BPCI and, 73

clinical data and, 105–107

criteria for, 108

exclusivity and, 80

FDA requirements for, 81, 82
 formulary management and, 84–85
 in practice, 82
 of small molecules, 84
 state legislation on, 83
 what it is not, 81–82

International Conference on Harmonization, Q5E, 27

Inventory management, 159

Investigational new drug application, 127

Ion exchange chromatography, 42–43

Ipilimumab
 as blockbuster, 2
 manufacturing changes and, 27
 price increase for, 7

Iso-aspartic acid development, 44

Isoelectric focusing, 42, 43

Italian Group for Inflammatory Bowel Disease, 62

L

Labeling, 79, 98–99

Ligand conjunction, 44–45

Liquid chromatography, 36

M

Mad cow disease, 116

Managed care growth, 14

Manufacturing
 biologic variation and, 24–26
 change types for, 28
 changes for monoclonal antibodies, 27–28
 high quality for all pharmaceuticals and, 29
 product purification issues in, 24
 protein extraction and, 24
 of recombinants, 21–24

Mass spectrometry, 36

Mechanisms of action, 72, 98

Medicaid, 147

Medical benefit, 142–144

Medicare
 average sales price and, 144
 Part A, 142–143
 Part B, 142–143, 145–146
 Part D, 142–143, 147–148

Medicare Prescription Drug, Improvement, and Modernization Act, 144

Merck, 122

Methionine, 44

Minimally clinically important difference, 95
 calculation of, 96

Momenta, 122

Monoclonal antibodies
 biosimilar functional characterization of, 44–45
 detailed representation of, 46
 global biosimilars for, 57
 glycosylation variations in, 47–48
 structure of, 45

Montelukast
 as blockbuster, 3, 4
 exclusivity and, 5

Muromonab-CD3, 2

MYL-1401H, 86

MYL-1401O, 86, 104

N

Naming biological products, 78, 158

Natalizumab, price increases, 7

New chemical entity, 128

New Drug Applications, 73–74, 158

Nivolumab, price increases, 7

NOR SWITCH trial, 83

O

- Omalizumab, price increases for, 7
- Originator biologics, 25–26, 129
- Orphan drug, 128
- Orthogonality
 - higher molecular weight/aggregation and, 39, 43
 - higher order structure and, 38, 41–42
 - post-translational modifications and, 39, 42–43, 44
 - primary structure and, 36, 37, 40–41
 - protein concentration and, 38
 - purity, charge heterogeneity, other variants and, 40

P

- Palivizumab, manufacturing changes, 27
- Panitumumab, manufacturing changes, 27
- Passthrough payments, 147
- Patent dance/litigation, 73, 129–130
 - originator reference product manufacturer notice and, 131–132
 - process for, 130
- Patent law
 - patient care experience and, 133
 - pharmacist and, 133
- Patent protection, 127–129
 - types of, 129–130
- Patent and Trademark Office, 127
- Patent Trial and Appeal Board, 132
- Patient
 - assistance programs, 148
 - care experience, 133
 - education, 162–163
 - population, 4
- Pediatric exclusivity, 128
- Pegfilgrastim
 - adverse reactions for, 115
 - auto injector for, 134
 - biosimilar for, 6, 86
 - as blockbuster, 3
 - expression system for, 23
 - extended dosing and, 134
 - price increases for, 7
- Pegfilgrastim-lfjd, 121
- Pembrolizumab
 - as blockbuster, 2
 - price increases for, 7
- PF-05280014, 86
- PF-05280586, 86
- Pfizer, 122
- Pharmacist
 - biosimilar financial benefit evaluation by, 148–149
 - biosimilarity validation and, 109
 - patent law and, 133–135
 - role in interchangeability, 84
- Pharmacodynamics, clinical trials and, 93
- Pharmacokinetics, clinical trials and, 93
- Pharmacovigilance, 113, 117, 119–120, 160
- Pharmacy
 - benefit for, 142–144
 - distribution and, 140–141
 - originator or biosimilar decision by, 164
- Pharmacy Benefit Manager, 143, 144–145
- Physician education, 161–162
- Physician Fee Schedule, 147
- Pioglitazone, exclusivity, 5
- PLANETAS studies, 99, 102
- PLANETRA studies, 99, 102
- Post-translational modifications, 39–40, 42–44
- PR-06439535, 86
- Pricing increases, 6–8

Prompt payment, 141

Protein

concentration, 38

extraction, 24

structure, 41

Public Health Service Act, 142

Pure red cell aplasia, 94, 116, 117

Purity, 40

Purple Book, 83–84

Q

Quality target product profile, 34

Quetiapine

as blockbuster, 3

exclusivity and, 5

R

Ramobozumab, 7

Recombinant technology, 1–2, 21, 75

Reference pricing, 60

Risk evaluation mitigation strategies, 73

Rituximab

adverse reactions to, 115

amino acid sequence errors and, 41

biosimilar for, 6

as blockbuster, 3

clinically importance antibodies to, 118

expression system for, 23

Fc and Fab binding and, 47

Fc and Fab regions of, 46, 51

as intravenous injection, 134

IPR and, 132

manufacturing changes and, 27

new biosimilars for, 168

price increases for, 7

Rosuvastatin, as blockbuster, 3

S

Sandoz Inc v. Amgen Inc, 130, 131–132

Savings estimates, 139–140

Single switch study, 109

Size exclusion chromatography, 43

Small molecules, 72–73, 146

Sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, 43

Somatropin

administration of, 133

anti-growth hormone antibodies and,
117

drug approval of, 75

expression system for, 23

global biosimilars for, 57

Specialty distribution, 141–142

Specialty pharmacy, 8, 145

Standard of care, 134

Substitutability, 84–85

Substitution, 63, 65–66

Surveillance information, 122

Switching studies, 107–108

T

Tbo-filgrastim, 121

Therapeutic interchange strategies, 123

340B program, 142

Tipping point analysis, 97

Tocilizumab

manufacturing changes and, 27

price increases for, 7

Trastuzumab

adverse reactions with, 115

biosimilar for, 6, 86

expression system for, 23

Fab and Fc regions of, 51

IPR, 132

manufacturing changes and, 27

orphan exclusivity and, 105

price increases for, 7

Tryptophan, 44

U

United States Adopted Names, 120

Ustekinumab, price increases for, 7

V

Volume-based discounts, 141

W

Western blotting, 43

White bagging, 145

Wholesaler acquisition cost (WAC),
140–141

World Health Organization, 120
and biologic qualifier, 121

World Marrow Donor Association, 61